AIHC Capital: Funding, Team & Investors

AIHC Capital Management Limited is a Hong Kong-based asset management firm exclusively focused on the global healthcare sector. The company strategically invests in entrepreneurial ventures developing solutions for critical unmet medical needs. This specialized approach fosters innovation and contributes to significant medical advancements.

Established in Hong Kong in 2018, AIHC Capital was co-founded by individuals including Wei Zhang. The firm's genesis stemmed from the insight that targeted investment in the dynamic healthcare landscape, particularly where significant medical challenges persist, offered substantial opportunities for growth.

The firm serves investors seeking returns from the specialized healthcare industry, backing companies across various development stages. AIHC Capital envisions itself as a crucial financial partner for healthcare entrepreneurs, providing resources to bring innovative medical solutions to market. Its mission is to accelerate global healthcare progression.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 1, 2024	Orange Dental	$130.0M Series B	Oceanpine Capital, OrbiMed	3W Capital, Adjuvant Capital, Eight Roads Ventures, F Prime Capital, Haitong International, Hillhouse Capital Group, MSA Capital, Superstring Capital
Mar 27, 2023	ArriVent Biopharma	$155.0M Series B	Elena Viboch, James Healy	Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, ZOO Capital
Mar 4, 2022	InxMed	$50.0M Series B	HUA YI	Growth Fund, Hosencare Fund
Aug 17, 2021	Meditrust	$308.7M Series C	Boyu Capital, Janchor Partners	Bank OF China Group Investment, China Everbright, China Renaissance, CICC Capital, Lake Bleu Capital, Lilly Asia Ventures, Marathon Venture Partners, NEW Alliance Capital, Shanghai Biopharmaceutical Fund, Sinovation Ventures
Jun 29, 2021	OnCusp Therapeutics	$25.0M Seed	Lynn Yang	Oriza Ventures
Feb 1, 2021	LakeShore Biopharma	$130.0M Series B	OrbiMed, Dave Chenn	3W Capital, Adjuvant Capital, Eight Roads Ventures, Epiphron Capital, F Prime Capital, Haitong International, Hillhouse Capital, MSA Capital, Superstring Capital
Sep 1, 2020	InventisBio	$150.0M Series D	Hillhouse Affiliate GL Ventures	Qiming Venture Partners, Advantech Capital, CMB International, Dyee Capital, Janchor Partners, Lilly Asia Ventures, Matrix Partners China, OrbiMed, Pudong Innotek
Nov 9, 2019	Akeso	$150.0M Series D	Loyal Valley Capital, Sino Biopharmaceutical	CDG International, Lake Bleu Capital, OrbiMed, Shenzhen Capital Group

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 1, 2024	Orange Dental	$130.0M Series B	Oceanpine Capital, OrbiMed	3W Capital, Adjuvant Capital, Eight Roads Ventures, F Prime Capital, Haitong International, Hillhouse Capital Group, MSA Capital, Superstring Capital
Mar 27, 2023	ArriVent Biopharma	$155.0M Series B	Elena Viboch, James Healy	Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, ZOO Capital
Mar 4, 2022	InxMed	$50.0M Series B	HUA YI	Growth Fund, Hosencare Fund
Aug 17, 2021	Meditrust	$308.7M Series C	Boyu Capital, Janchor Partners	Bank OF China Group Investment, China Everbright, China Renaissance, CICC Capital, Lake Bleu Capital, Lilly Asia Ventures, Marathon Venture Partners, NEW Alliance Capital, Shanghai Biopharmaceutical Fund, Sinovation Ventures
Jun 29, 2021	OnCusp Therapeutics	$25.0M Seed	Lynn Yang	Oriza Ventures
Feb 1, 2021	LakeShore Biopharma	$130.0M Series B	OrbiMed, Dave Chenn	3W Capital, Adjuvant Capital, Eight Roads Ventures, Epiphron Capital, F Prime Capital, Haitong International, Hillhouse Capital, MSA Capital, Superstring Capital
Sep 1, 2020	InventisBio	$150.0M Series D	Hillhouse Affiliate GL Ventures	Qiming Venture Partners, Advantech Capital, CMB International, Dyee Capital, Janchor Partners, Lilly Asia Ventures, Matrix Partners China, OrbiMed, Pudong Innotek
Nov 9, 2019	Akeso	$150.0M Series D	Loyal Valley Capital, Sino Biopharmaceutical	CDG International, Lake Bleu Capital, OrbiMed, Shenzhen Capital Group

AIHC Capital

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Deep Dive

Sources

Deep Dive

Sources

Investment Activity

Investments Made